In this SOHO Insider roundtable discussion, Charalambos (Babis) Andreadis, MD, MS, professor of clinical medicine at University of California, moderates a discussion on CELLMods in lymphoma.
The panelists include Jason Westin, MD, associate professor in the Department of Lymphoma/Myeloma at University of Texas MD Anderson Cancer Center; Loretta Nastoupil, MD, section chief of indolent lymphoma and director of clinical research at Common Spirit Health; and Swetha Thiruvengadam, MD, assistant clinical professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope.
In this video, the group discusses the 2025 DLBCL treatment landscape.
“We have gone from having R-CHOP and chemotherapy in the second link to to having an embarrassment of riches, basically a wealth of new drugs coming along,” Dr. Westin said. “Many new drugs have been approved in the relapse/refractory space, including CAR-T cell therapies, bispecifics, some targeted antibody drug conjugates, and now a lot of these drugs are being looked at in the frontline space.”
This video is being brought to you by an education grant by Bristol Myers Squibb.
